Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin®) For The Treatment Of Three Types Of Cancer

Author's Avatar
Mar 23, 2018
Article's Main Image

Recommended for Approval for the Same Indications as Herceptin® (Trastuzumab)

Positive Opinion for ABP 980 is Supported by Phase 3 Data in Patients With HER2-Postive Early Breast Cancer

PR Newswire